Study wrapper · #20
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
Editor's note
This in-vitro study is the first to characterise BPC-157 and two rationally designed hybrid analogs — CIARA-1 and CIARA-2 — as reversible competitive inhibitors of acetylcholinesterase (AChE), an enzyme central to cholinergic signalling and a well-established drug target in Alzheimer's disease. Researchers found that CIARA-1 showed the highest inhibitory potency (Ki = 0.24 mM; IC50 = 2.52 mM), followed by CIARA-2 and BPC-157 itself, with findings consistent with molecular modelling predictions.
The critical caveat is one the authors state plainly: potency across all three compounds is substantially lower than clinically used AChE inhibitors such as donepezil or galantamine. An IC50 in the low-millimolar range is orders of magnitude weaker than approved drugs operating in the nanomolar range. This is an early-stage mechanistic signal, not evidence of therapeutic applicability.
For BPC-157's broader evidence landscape, this study opens a genuinely novel mechanistic avenue — the peptide's potential to interact with cholinergic pathways had not been formally explored prior to this work. However, these are in-vitro findings only; human data are entirely absent. The authors...
Plain-language abstract
Researchers investigated whether BPC-157 — a synthetic 15-amino-acid peptide derived from human gastric juice — and two newly designed variants called CIARA-1 and CIARA-2 could block an enzyme called acetylcholinesterase (AChE). AChE breaks down the neurotransmitter acetylcholine, and inhibiting it is one of the main strategies used in managing neurodegenerative conditions such as Alzheimer's disease.
The two hybrid peptides were purpose-built by attaching a fragment of BPC-157 to an arginine-rich sequence intended to improve how the molecules interact with the enzyme's binding sites. Using standard lab-based enzyme activity tests — performed in a test tube rather than in animals or humans — the researchers measured how strongly each compound interfered with AChE function.
All three compounds blocked AChE through a competitive mechanism, meaning they competed directly with the enzyme's natural substrate at the same binding site without permanently disabling the enzyme. CIARA-1 showed the strongest inhibitory effect, with BPC-157 itself performing least potently of the three.
Importantly, the researchers noted that all three compounds were substantially less potent than AChE-inhibiting drugs already used in clinical practice. No cell toxicity or adverse effects were reported in the abstract, though this was a test-tube study rather than a biological organism. These are preclinical, in-vitro findings; human data are needed before any clinical conclusions can be drawn....